“Bogotá Your Home”: A Showcase of Bogotá’s New Image at COP16

Share

BOGOTÁ, COLOMBIA / ACCESSWIRE / October 29, 2024 / "Bogotá tu casa" - "Bogotá Your Home", a campaign led by the District Institute of Tourism in collaboration with the Bogotá Chamber of Commerce and Invest in Bogotá, was showcased at COP16 to hundreds of visitors. The campaign highlighted the capital's key attributes and opportunities for tourists, entrepreneurs, and investors.

"As Invest in Bogotá, we supported this activation to show the world why Bogotá is a city full of opportunities for businesspeople, investors, and global-scale events. We look forward to guiding international decision-makers in exploring the city's investment opportunities as a platform for business expansion and growth", said Isabella Muñoz.

"Bogotá Your Home," the new campaign by the Bogotá District Institute of Tourism, the Bogotá Chamber of Commerce, and Invest in Bogotá, was promoted at COP16.

The event took place at the House of Bogotá and the Bogotá Chamber of Commerce at Bulevar del Río in Cali, the host city for the world's largest biodiversity summit. Attendees enjoyed an urban music show, a large-scale graffiti installation inspired by Bogotá's landscapes and ecosystems, and other activities.

"We are here proudly representing Bogotá, showcasing a city of opportunities that welcomes both locals and visitors. We strive to make Bogotá even greater because it deserves more", stated Ovidio Claros Polanco, Executive President of the Bogotá Chamber of Commerce.

The event also featured a digital photography exhibition titled "Bogotá, a Biodiverse Destination", which presented 16 of the capital's key green and conservation sites, such as wetlands, trails, viewpoints, and the stunning Sumapaz paramo.

The exhibition aimed to encourage visitors to discover these natural treasures, serving as both a visual portfolio and a tourist guide to explore Bogotá's biodiversity and its balance between urban and natural environments.

The campaign "Bogotá Your Home" seeks to captivate and inspire both locals and visitors, building trust and emotional connections. It is the result of a well-coordinated effort between the Mayor's Office of Bogotá, the Bogotá Chamber of Commerce, and Invest in Bogotá, institutions committed to the city's development and competitiveness. [Watch the official campaign video here.]

"Bogotá Your Home at COP16 exemplifies how coordinated tourism efforts between the Chamber of Commerce and Invest in Bogotá can strengthen the city's competitiveness and development", emphasized Andrés Santamaría, director of the District Institute of Tourism (IDT).

One of the most significant milestones of this campaign will take place on November 4th in New York City, when the campaign will light up the screens of Times Square to evoke emotions, build trust, and spark the interest of potential tourists, entrepreneurs, and investors, especially from the North American market.

"Path to Biodiversity Compliance from a Local Perspective"

During the weekend, the city's investment promotion agency also participated in several activities, including the panel discussion "Path to Biodiversity Compliance from a Local Perspective." This panel provided a space for exchanging experiences with local and regional stakeholders on developing tools and implementing actions to meet national and international biodiversity conservation goals.

Invest in Bogotá participated in the panel "Path to Biodiversity Compliance from a Local Perspective" at COP16.

Bogotá has already begun implementing an integrated strategy across land, air, and water to reduce pollution. This strategy includes restoring the eastern hills, participatory and efficient management of the city's main ecological structure, improving environmental quality-particularly in the city's southwest-and comprehensive watershed management, among other initiatives.

However, Mayor Carlos Fernando Galán called for greater inclusion of local administrations in these discussions: "It is essential that subnational governments have a voice that is heard. We possess the tools and the highest capacity to act in our territories. However, since we are not part of the negotiation stage, our voices often go unheard", he acknowledged.

Later, Invest in Bogotá participated in the CAF's (Andean Development Corporation) joint commitment to sustainable cities and biodiversity, where cities like Bogotá and Santa Marta prioritized nature conservation. The event also included the First Meeting of the Mayors' Forum on Urban Nature and Biodiversity, a space where cities reaffirmed their commitment to urban nature and biodiversity and called for increased funding for these efforts.

Signing of the Capital Cities Commitment -#BiodiverCities- to further integrate biodiversity into planning and sustainable development.

COP16 aims to establish agendas, commitments, and frameworks for conserving biological diversity, promoting sustainable use, and ensuring fair and equitable sharing of the benefits derived from genetic resources. The summit will conclude its agenda in Cali on November 1st.

Contact information

Phone number: (+57) 317 780 6158
Email: info@investinbogota.org

SOURCE: Invest in Bogota



View the original press release on accesswire.com

Invest in Bogota

Subscribe to releases from Accesswire

Subscribe to all the latest releases from Accesswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Accesswire

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press Release

Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera

Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press Release

During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h

Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press Release

WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and

ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press Release

TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press Release

Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye